Development of Engineered T Cells Expressing a Chimeric CD16-CD3 Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-2714
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

High-Affinity CD16-polymorphism and Fc-Engineered Antibodies Enable Activity of CD16-chimeric Antigen Receptor-Modified T Cells for Cancer Therapy

British Journal of Cancer
Cancer ResearchOncology
2018English

Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Immunotherapy
OncologyAllergyImmunology
2016English

Genetically Engineered T Cells Expressing a HER2-specific Chimeric Receptor Mediate Antigen-Specific Tumor Regression

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2008English

768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells

Journal of Immunology
AllergyImmunology
2017English

CML Hematopoietic Stem Cells Expressing IL-1RAP Can Be Targeted by Chimeric Antigen Receptor (CAR)-engineered T Cells

Cancer Research
Cancer ResearchOncology
2018English

Pre-Clinical Evaluation of CD38 Chimeric Antigen Receptor Engineered T Cells for the Treatment of Multiple Myeloma

Haematologica
Hematology
2016English

CD3 Down-Regulating Factor in Patients With Adult T Cell Leukemia.

Japanese Journal of Clinical Immunology
1993English

Development of a Wilms' Tumor Antigen-Specific T-Cell Receptor for Clinical Trials: Engineered Patient's T Cells Can Eliminate Autologous Leukemia Blasts in NOD/SCID Mice

Haematologica
Hematology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy